Back to Stocks

RARE

Ultragenyx Pharmaceutical Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Ultragenyx is currently positioned at a pivotal transition point, evolving from a clinical-stage entity into a commercial leader in the rare disease space.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic pipeline narrative, the quarterly filing reveals a concerning fiscal trajectory characterized by aggressive cash burn and mounting liabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every RARE filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a high-stakes trade-off between imminent binary regulatory events and deteriorating fundamental financial metrics. On one hand, the acceptance of BLAs for DTX401 and UX111 provides a clear, time-bound catalyst that could fundamentally re-rate the company's valuation if approvals are granted. The strategic restructuring and workforce cuts signal a management team focused on fiscal discipline as they approach the commercialization phase of their gene therapy portfolio. However, the underlying financial data shows a company heavily reliant on external financing and royalty monetization to sustain operations. The combination of a $1.5 billion royalty liability, ongoing generic litigation for Dojolvi, and a significant quarterly net loss underscores the volatility inherent in the business model. Investors must weigh the potential for a commercial explosion in late 2026 against the risk of a liquidity crunch or regulatory setback that could jeopardize the company's long-term viability.

Selected Quarter

Core Takeaway

Ultragenyx is racing against a ticking financial clock to secure regulatory approvals for DTX401 and UX111 before its cash runway tightens and generic competition hits Dojolvi.

Investor Lens

The trade-off is between the high-reward potential of the 2026 regulatory catalysts and the systemic risk of the company's debt-like royalty obligations.

Watch Next

The August 23, 2026 PDUFA date for DTX401.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%
bearishMay 6

Net loss of $185 million for the quarter reflects continued high burn rate.

earnings miss
70%
neutralMay 6

Implemented a strategic restructuring plan including a 10% workforce reduction.

management change
40%
bullishMay 6

FDA accepted BLAs for DTX401 and UX111 with Priority Review and set PDUFA dates for late 2026.

regulatory action
90%
bullishMay 6

Maintained strong gross margins of approximately 78% on product sales.

margin expansion
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a high-stakes trade-off between imminent binary regulatory events and deteriorating fundamental financial metrics. On one hand, the acceptance of BLAs for DTX401 and UX111 provides a clear, time-bound catalyst that could fundamentally re-rate the company's valuation if approvals are granted. The strategic restructuring and workforce cuts signal a management team focused on fiscal discipline as they approach the commercialization phase of their gene therapy portfolio. However, the underlying financial data shows a company heavily reliant on external financing and royalty monetization to sustain operations. The combination of a $1.5 billion royalty liability, ongoing generic litigation for Dojolvi, and a significant quarterly net loss underscores the volatility inherent in the business model. Investors must weigh the potential for a commercial explosion in late 2026 against the risk of a liquidity crunch or regulatory setback that could jeopardize the company's long-term viability.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.